Lithia & Driveway (LAD) Schedules Release of Second Quarter 2026 Results

MEDFORD, Ore., July 14, 2026 (GLOBE NEWSWIRE) — Lithia & Driveway (NYSE: LAD) today announced its second quarter 2026 results will be released before the market opens on Wednesday, July 29, 2026. A conference call to discuss the earnings results is scheduled for the same day at 10:00 a.m. Eastern Time.

How to Participate

The conference call may be accessed by telephone at (877) 407-8029. To listen live on our website, or for replay, visit investors.lithiadriveway.com and click on quarterly earnings.

About Lithia & Driveway (LAD)

Lithia & Driveway (NYSE: LAD) is the largest global automotive retailer making Auto Done Easy by providing simple, transparent, and convenient experiences throughout the ownership lifecycle. LAD helps customers take care of any vehicle need through a comprehensive network of physical locations, e-commerce platforms, captive finance solutions, fleet management offerings, and other synergistic adjacencies. Celebrating 80 years in business in 2026, LAD consistently delivers profitable growth in a massive and unconsolidated industry. Its highly diversified and competitively differentiated design provides LAD with the flexibility and scale to pursue its vision to modernize personal transportation solutions wherever, whenever and however consumers desire.

The 80th Celebration

https://www.lithiadriveway.com/80-years

Connect with Us!

All Cars: https://www.lithia.com
Driveway.com (Buy, sell, trade, or finance entirely online): https://www.driveway.com
GreenCars (All things sustainable vehicles): https://www.greencars.com
DFC (Auto Financing): https://www.drivewayfinancecorp.com
Investor Relations: https://investors.lithiadriveway.com/
Careers: https://www.lithiacareers.com
Lithia & Driveway on Instagram
https://www.instagram.com/lithiamotors/?hl=en
https://www.instagram.com/driveway_hq/
Lithia & Driveway on Facebook
https://www.facebook.com/lithiaanddriveway/
https://www.facebook.com/DrivewayHQ
Lithia & Driveway on X
https://x.com/lithiadriveway
https://x.com/DrivewayHQ
https://x.com/GreenCarsHQ
Lithia & Driveway on LinkedIn
https://www.linkedin.com/company/lithia-motors/
Lithia & Driveway on YouTube
https://www.youtube.com/@LithiaDriveway

Media Contact

[email protected]  



Nayax: information security incident update

HERZLIYA, Israel, July 14, 2026 (GLOBE NEWSWIRE) — Further to Nayax’s announcement dated July 8, 2026, regarding a suspected information security incident, the Company provides the following update.

The Company’s system review and technical remediation activities have been completed, and the Company’s systems have been cleared and based on its investigation to date, confirmed to be free of unauthorized access. The Company’s production environment and core systems have not been impacted. The Company’s business operations continue as normal, without disruption or impact on our operations.

As the Company’s investigation progressed, and while the precise scope and complete contents of the exfiltrated information are still under investigation, findings have emerged indicating that such exfiltrated information includes a copy of a backup of scanned documents,  additional business-related information, and mainly back up of payment transaction records which does not include sensitive payment authentication data (such as cardholder names, CVV values or ID information), as such information is generally not retained within the Company’s systems. In addition, a significant portion of the transactions were conducted using digital wallets, such as Apple Pay and Google Pay, in which the payment credentials consist of single-use tokens that have no value if disclosed. Based on its investigation to date, the Company confirms that all customer safeguarded funds were untouched and that no unauthorized access to those accounts occurred.

The Company’s Board of Directors has resolved not to comply with criminal extortion demands. The Board believes that complying with such demands would not be consistent with the long-term best interests of the Company’s customers, partners, employees and shareholders.

The Company has incurred, and may continue to incur, costs related to responding to, remediating, and investigating this attack. The full financial impact-including insurance or indemnification offsets and any effect on customer behavior-is not yet determined, but the Company does not currently expect a material effect on its financial condition or results of operations.

The Company continues to cooperate fully and closely with the relevant law enforcement authorities, which continue to conduct an intensive investigation into the incident and those responsible.

Nayax Public Relations Contact: 
Scott Gamm 
Strategy Voice Associates 
[email protected] 

Nayax Investor Relations Contact: 
Aaron Greenberg 
Chief Strategy Officer 
[email protected] 



Nordic Firms Seek Green, Sovereign AI Infrastructure

Nordic Firms Seek Green, Sovereign AI Infrastructure

Renewable power, heat reuse and local data requirements are reshaping private and hybrid cloud choices, ISG Provider Lens® report says

STOCKHOLM–(BUSINESS WIRE)–
Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations.

“Nordic enterprises are connecting infrastructure decisions to resilience, data control and sustainability rather than treating cloud as a capacity purchase,” said Susanta Dey, director, ISG EMEA Cloud and Tech Modernization Practice. “As AI operations require more energy and tighter governance, they are looking for hybrid environments that can scale without weakening sovereignty or environmental commitments.”

Sustainability has become central to infrastructure sourcing in the Nordics as enterprises move beyond power usage effectiveness to require heat reuse, renewable energy and closer integration with local energy systems. Metropolitan areas such as Stockholm and Helsinki are mandating that data centers contribute to district heating, making energy circularity an important consideration for AI and high-performance computing workloads.

Digital sovereignty is also reshaping Nordic cloud strategies. Enterprises are seeking Nordic-only cloud instances and stronger assurances that sensitive data, operations and controls remain within the European Economic Area. These requirements reflect concerns about international data access laws and regional security risks, especially for regulated sectors that need resilient facilities and clear jurisdictional control.

Nordic enterprises are also reassessing how they manage infrastructure complexity as AI and generative AI become more widely used. Buyers seek providers that can move GenAI from pilots into industrial-scale operations with measurable outcomes. At the same time, an ongoing regional talent shortage is expected to increase adoption of agentic AI for IT operations (AIOps) to automate processes, maximizing the efficiency of IT teams, ISG says.

“The Nordics are becoming a proving ground for infrastructure that is sustainable, sovereign and AI-ready,” said Meenakshi Srivastava, ISG lead analyst and lead author of the report. “Providers that combine local operating knowledge, automation and high-density capacity will be most useful to enterprises balancing performance with control.”

The report also explores other trends shaping the Nordic market, including selective insourcing to retain critical architecture skills and the increasing use of liquid and immersion cooling in colocation services.

For more insights into the private and hybrid cloud-related challenges faced by enterprises in the Nordics, plus ISG’s advice for overcoming them, see the ISG Provider Lens Focal Points briefing here.

The report evaluates the capabilities of 54 providers across four quadrants: AI-ready Infrastructure Managed Services — Large Accounts, AI-ready Infrastructure Managed Services — Midmarket, Managed Cloud Hosting and Resilient Infrastructure Services and Sustainable Colocation Services.

The report names Orange Business and Vivicta as Leaders in three quadrants each. Atea, Kyndryl and Sopra Steria are named as Leaders in two quadrants each. Accenture, Bulk Infrastructure, Capgemini, CGI, Digital Realty, Equinix, Fujitsu, Green Mountain, HCLTech, Infosys, LTM, STACK Infrastructure, TCS, Tech Mahindra and Wipro are named as Leaders in one quadrant each.

In addition, Advania, Cognizant and Verne are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant.

In the area of customer experience, CS Global IT is named the global ISG CX Star Performer for 2026 among private/hybrid cloud and data center service providers. CS Global IT earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

A customized version of the report is available from Vivicta.

The 2026 ISG Provider Lens Private/Hybrid Cloud — Data Center Services report for the Nordics is available to subscribers or for one-time purchase on this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Press Contacts:

Laura Hupprich, ISG

+1 203-517-3132

[email protected]

Philipp Jaensch, ISG

+49 151 730 365 76

[email protected]

KEYWORDS: Sweden Europe

INDUSTRY KEYWORDS: Software Internet Professional Services Business Data Management Sustainability Technology Artificial Intelligence Environment Security Data Analytics Green Technology

MEDIA:

Logo
Logo

SemiLEDs Reports Third Quarter Fiscal Year 2026 Financial Results

SemiLEDs Reports Third Quarter Fiscal Year 2026 Financial Results

HSINCHU, Taiwan–(BUSINESS WIRE)–
SemiLEDs Corporation (NASDAQ: LEDS), “SemiLEDs” or the “Company,” a developer and manufacturer of LED chips and LED components, today announced its financial results for the third quarter of fiscal year 2026, ended May 31, 2026.

Revenue for the third quarter of fiscal 2026 was $9.1 million, compared to $1.1 million in the second quarter of fiscal 2026. GAAP net income attributable to SemiLEDs stockholders for the third quarter of fiscal 2026 was $1.5 million, or $0.18 per diluted share, compared to a net loss of $603 thousand, or $(0.07) per diluted share, in the second quarter of fiscal 2026.

GAAP gross margin for the third quarter of fiscal 2026 was 27%, compared to 1% for the second quarter of fiscal 2026. Operating margin for the third quarter of fiscal 2026 was 16%, compared with negative 79% for the second quarter of fiscal 2026. The Company’s cash and cash equivalents were $6.0 million at May 31, 2026, compared to $4.0 million at the end of the second quarter of fiscal 2026.

Our revenue was higher in the third quarter of fiscal 2026 compared to the second quarter of fiscal 2026, due to the increase of buy-sell purchase orders of equipment. We anticipate more buy-sell purchase orders in the fourth quarter of fiscal 2026.

About SemiLEDs

SemiLEDs develops and manufactures LED chips and LED components for general lighting applications, including street lights and commercial, industrial, system and residential lighting, along with specialty industrial applications such as ultraviolet (UV) curing, medical/cosmetic, counterfeit detection, horticulture, architectural lighting and entertainment lighting. SemiLEDs sells blue, white, green and UV LED chips.

Forward Looking Statements

This press release contains statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward-looking, including any statements regarding the expectation of buy-sell orders in the second half of fiscal 2026; any statements about historical results that may suggest trends for SemiLEDs’ business; any statements of the plans, strategies and objectives of management for future operations; any statements of expectation or belief regarding recovery of the LED industry, market opportunities and other future events or technology developments; any statements regarding SemiLEDs’ position to capitalize on any market opportunities; and any statements of assumptions underlying any of the foregoing. These forward-looking statements are based on current expectations, estimates, forecasts and projections of future SemiLEDs’ or industry performance based on management’s judgment, beliefs, current trends and market conditions and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. SemiLEDs’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) and other SemiLEDs filings with the SEC (which you may obtain for free at the SEC’s website at http://www.sec.gov) discuss some of the important risks and other factors that may affect SemiLEDs’ business, results of operations and financial condition. SemiLEDs undertakes no intent or obligation to publicly update or revise any of these forward looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SEMILEDS CORPORATION AND SUBSIDIARIES

Unaudited Condensed Consolidated Balance Sheets

(In thousands of U.S. dollars)

 

 

May 31,

 

 

February 28,

 

 

 

2026

 

 

2026

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

$

5,978

 

 

$

3,978

 

Accounts receivable (including related parties), net

 

 

2,193

 

 

 

1,649

 

Inventories, net

 

 

4,739

 

 

 

4,885

 

Prepaid expenses and other current assets

 

 

960

 

 

 

1,937

 

Total current assets

 

 

13,870

 

 

 

12,449

 

Property, plant and equipment, net

 

 

2,263

 

 

 

2,353

 

Operating lease right of use assets

 

 

1,007

 

 

 

1,047

 

Intangible assets, net

 

 

106

 

 

 

110

 

Investments in unconsolidated entities

 

 

47

 

 

 

49

 

Other assets

 

 

250

 

 

 

252

 

TOTAL ASSETS

 

$

17,543

 

 

$

16,260

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Current installments of long-term debt

 

$

1,262

 

 

$

1,265

 

Accounts payable

 

 

4,874

 

 

 

2,157

 

Accrued expenses and other current liabilities

 

 

6,057

 

 

 

8,924

 

Other payable to related parties

 

 

1,187

 

 

 

1,170

 

Operating lease liabilities, current portion

 

 

107

 

 

 

127

 

Total current liabilities

 

 

13,487

 

 

 

13,643

 

Long-term debt, excluding current installments

 

 

77

 

 

 

193

 

Operating lease liabilities, less current portion

 

 

900

 

 

 

920

 

Total liabilities

 

 

14,464

 

 

 

14,756

 

Commitments and contingencies

 

 

 

 

 

 

SHAREHOLDERS‘ EQUITY:

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

Additional paid-in capital

 

 

189,063

 

 

 

189,020

 

Accumulated other comprehensive income

 

 

3,649

 

 

 

3,640

 

Accumulated deficit

 

 

(189,633

)

 

 

(191,156

)

Total shareholders’ equity

 

 

3,079

 

 

 

1,504

 

TOTAL LIABILITIES AND EQUITY

 

$

17,543

 

 

$

16,260

 

SEMILEDS CORPORATION AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Operations

(In thousands of U.S. dollars and shares, except per share data)

 

 

Three Months Ended

 

 

 

May 31, 2026

 

 

February 28, 2026

 

Revenues, net

 

$

 

9,074

 

 

$

 

1,064

 

Cost of revenues

 

 

 

6,614

 

 

 

 

1,058

 

Gross profit

 

 

 

2,460

 

 

 

 

6

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

 

363

 

 

 

 

276

 

Selling, general and administrative

 

 

 

681

 

 

 

 

575

 

Gain on disposals of long-lived assets, net

 

 

 

1

 

 

 

 

 

Total operating expenses

 

 

 

1,045

 

 

 

 

851

 

Income (loss) from operations

 

 

 

1,415

 

 

 

 

(845

)

Other income (expenses):

 

 

 

 

 

 

 

 

Investment loss from unconsolidated entities

 

 

 

(2

)

 

 

 

(6

)

Interest expenses, net

 

 

 

(10

)

 

 

 

(22

)

Other income, net

 

 

 

270

 

 

 

 

275

 

Foreign currency transaction (loss) gain, net

 

 

 

(150

)

 

 

 

(5

)

Total other income, net

 

 

 

108

 

 

 

 

242

 

Income (loss) before income taxes

 

 

 

1,523

 

 

 

 

(603

)

Income tax expense

 

 

 

 

 

 

Net income (loss)

 

$

 

1,523

 

 

$

 

(603

)

Net income (loss) per share

 

 

 

 

 

 

 

 

Basic and diluted

 

$

 

0.18

 

 

$

 

(0.07

)

Weighted average number of ordinary shares outstanding

 

 

 

 

 

 

 

 

Basic and diluted

 

 

 

8,264

 

 

 

 

8,225

 

 

Christopher Lee

Chief Financial Officer

SemiLEDs Corporation

+886-37-586788

[email protected]

KEYWORDS: Taiwan Asia Pacific

INDUSTRY KEYWORDS: Semiconductor Consumer Electronics Technology Manufacturing Other Manufacturing Hardware

MEDIA:

Logo
Logo

De Tomaso Advances Next-Generation V12 Programme with Italtecnica

HONG KONG and TURIN, Italy, July 14, 2026 (GLOBE NEWSWIRE) — OIO Group (NASDAQ: OIO) today announced its collaboration with Italtecnica Engineering on De Tomaso’s next-generation V12 programme, as prototype bench testing commences following the successful completion of the engine’s design and engineering phase.

De Tomaso’s next-generation V12 is a clean-sheet, bespoke powertrain engineered exclusively for the marque. Rather than adapting an existing OEM engine architecture, the programme has been conceived from first principles to embody De Tomaso’s vision of mechanical purity, analogue driving and timeless automotive craftsmanship.

The clean-sheet architecture provides complete engineering freedom to define every aspect of the engine’s character—from its combustion architecture and performance characteristics to its acoustics, throttle response and emotional driver engagement. The result is a powertrain designed to become an integral part of the next generation of De Tomaso automobiles, rather than simply its source of propulsion.

With prototype bench testing now underway, the programme enters the critical validation phase, where the engine will undergo comprehensive durability, calibration, thermal management and performance testing before progressing to vehicle integration.

Carlo Cavagnero, Technical Director of Italtecnica Engineering, said:

“A clean-sheet V12 programme of this nature has become exceptionally rare in today’s automotive industry. Developing an engine entirely from first principles gives us the freedom to define every aspect of its character without compromise—from its responsiveness and performance to its acoustics and emotional engagement. Rather than adapting an existing production architecture, we have engineered a powertrain specifically around De Tomaso’s vision. That level of engineering focus is what makes this programme truly special.”

Norman Choi, Chairman and Chief Executive Officer of OIO Group, said:

“A bespoke V12 programme is a deliberate strategic decision. It allows De Tomaso to own the engineering DNA that will define every future De Tomaso automobile—from its performance and sound to the emotional connection it delivers behind the wheel. Our collaboration with Italtecnica brings together a specialist Motor Valley engineering team with De Tomaso’s vision for the future. The commencement of prototype bench testing marks another step forward as we continue building the next generation of De Tomaso automobiles. This is the standard of execution we intend across the group.”

At a time when clean-sheet internal combustion engine programmes have become increasingly uncommon, De Tomaso’s next-generation V12 demonstrates the marque’s long-term commitment to engineering authenticity, craftsmanship and analogue performance.

OIO Group will continue to provide updates as the programme progresses through prototype validation, vehicle integration and the next stages of engineering development.

About OIO Group

OIO Group (NASDAQ: OIO) is a technology-driven industrial group with businesses spanning advanced sustainable materials, circular economy solutions and ultra-luxury automotive innovation. Through De Tomaso Automobili, OIO Group is committed to creating timeless, limited-production performance automobiles that combine Italian craftsmanship, engineering excellence and emotional design.

About Italtecnica Engineering

Headquartered in Italy’s renowned Motor Valley, Italtecnica Engineering is an independent engineering company specialising in the design, development and validation of bespoke high-performance internal combustion engines and advanced powertrain systems for premium and limited-production automotive manufacturers. Its expertise encompasses complete powertrain development, from concept engineering through prototype validation and production support. https://italtecnicaengineering.com/

Forward-Looking Statements

Certain statements in this press release may be considered to contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters , but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include, but are not limited to, the statements relating to the proposed acquisition of a privately held German-based specialist automotive engineering and production platform.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the current beliefs, expectations, and assumptions of management of OIO Group. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with the U.S. Securities and Exchange Commission (“SEC”) by the Company, including its Annual Report on Form 20-F filed with the SEC on April 20, 2026, and in other documents that the Company may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by the Company in this press release is based only on information currently available and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact

Investor Relations, OIO Group
Email: [email protected]
Website: www.oio.io



U.K. Firms Move to AI-Native, Sovereign Cloud Infrastructure

U.K. Firms Move to AI-Native, Sovereign Cloud Infrastructure

Organizations seek to modernize IT environments to balance resilience and sustainability as AI adoption accelerates, ISG Provider Lens® report says

LONDON–(BUSINESS WIRE)–
Enterprises in the U.K. are rethinking infrastructure strategies as AI workloads, energy constraints and evolving regulations change the conditions under which they operate, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the UK finds that changing economic conditions, tightening sustainability requirements and expanding AI deployments are reshaping enterprise infrastructure priorities. Organizations increasingly expect providers to deliver resilient, modular and sovereign infrastructure that supports evolving business requirements.

“AI is fundamentally changing how enterprises evaluate cloud infrastructure,” said Mathew Hannon, director and U.K. public sector lead, ISG. “Organizations increasingly expect providers to combine operational resilience, sustainable infrastructure and AI-enabled automation to support long-term business priorities.”

U.K. enterprises are seeking providers that can modernize legacy environments into containerized, AI-integrated platforms rather than maintaining them in a steady state. As official support ends for most legacy systems, organizations are implementing AI-ready foundations that reduce technical debt and accelerate innovation. These investments help enterprises support increasingly data-intensive, AI-driven workloads and overcome the limitations of legacy environments.

As generative AI moves from experimentation to production, companies are placing greater emphasis on sovereign infrastructure, secure data governance and private AI deployments. Organizations increasingly want to keep sensitive data and AI models within the U.K. to comply with evolving regulatory requirements and reduce cross-border risk. When making infrastructure decisions, they are balancing governance, jurisdictional control and performance.

U.K. enterprises are strengthening operational resilience by adopting FinOps practices and migrating from traditional disaster recovery to continuous availability across hybrid cloud environments. As workloads shift between public clouds, hosted infrastructure and edge systems, organizations are seeking greater visibility and cost control while addressing skills shortages. At the same time, providers are embedding AI for IT operations (AIOps) and machine learning operations (MLOps) into managed services and investing in sustainable infrastructure capable of supporting increasingly dense, GPU-intensive AI workloads.

“Organizations are evaluating infrastructure providers on their ability to support long-term transformation rather than isolated technology upgrades,” said Meenakshi Srivastava, lead analyst, ISG Provider Lens Research, and lead author of the report. “AI-ready capabilities, sovereign operations and sustainable infrastructure have become essential considerations in complex hybrid environments.”

The report also explores other trends shaping the U.K. market, including the growing role of regional edge infrastructure and the emergence of agentic IT, where AI agents automatically carry out Level 1 and Level 2 support tasks.

For more insights into the private/hybrid cloud and data center services-related challenges facing enterprises in the U.K., plus ISG’s advice for addressing them, see the ISG Provider Lens Focal Points briefing here.

The report evaluates the capabilities of 67 providers across four quadrants: AI-ready Infrastructure Managed Services — Large Accounts, AI-ready Infrastructure Managed Services — Midmarket, Managed Cloud Hosting and Resilient Infrastructure Services and Sustainable Colocation Services.

It names Claranet, Deutsche Telekom/T-Systems, DXC Technology, Hexaware, Kyndryl, NTT DATA, Pulsant and Rackspace Technology as Leaders in two quadrants each. Accenture, Atos, Capgemini, Coforge, Cognizant, Computacenter, CyrusOne, Digital Realty, Ensono, Equinix, Global Switch, HCLTech, Infosys, LTM, TCS, Telefónica Tech, Telehouse, Unisys, VIRTUS and Wipro are named as Leaders in one quadrant each.

In addition, Colt Tech Services, Kao Data, Microland and NTT DATA are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant each.

In the area of customer experience, CS Global IT is named the global ISG CX Star Performer for 2026 among private/hybrid cloud and data center service providers. CS GLOBAL IT earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

A customized version of the report is available from Rackspace.

The 2026 ISG Provider Lens Private/Hybrid Cloud — Data Center Services report for the U.K. is available to subscribers or for one-time purchase on this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Press Contacts:

Sarah Ye, ISG

+44 7833 567868

[email protected]

Laura Hupprich, ISG

+1 203-517-3132

[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Software Internet Professional Services Hardware Data Management Technology Artificial Intelligence Security Data Analytics Other Professional Services Other Technology Consulting

MEDIA:

Logo
Logo

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board

  • Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline
  • Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member
  • Appointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing

UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) — ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Chief Financial Officer, effective June 19, 2026, and the addition of Thomas A. West, a veteran U.S. medical technology leader, to its Board of Directors as an Independent Director, effective July 1, 2026.

Together, the appointments lay the financial and governance foundation for ViCentra to scale across Europe and enter the U.S. market following a year of sustained operational momentum. ViCentra closed a $98 million Series D financing, strengthened its leadership team, launched its smartphone-controlled Kaleido system with Diabeloop’s DBLG2 algorithm and Dexcom G7, and began commercial-scale production of Kaleido consumables through its manufacturing collaboration with Phillips Medisize, a Molex company. With manufacturing now at commercial scale and unit economics strengthening, ViCentra is adding the financial and strategic leadership to build on that foundation.

“Ian and Tom’s appointments further strengthen the leadership team that we have assembled to support our next stage of growth. Following the successful scale-up of our commercial manufacturing capabilities and continued improvements in unit economics, we are well positioned to build on this momentum. Their deep financial, strategic and operational expertise will be invaluable as we accelerate our expansion across Europe and prepare for entry in the U.S market. These appointments mark another important step in building a company poised to lead the future of diabetes care,” said Tom Arnold, Chief Executive Officer of ViCentra.

Wells joins ViCentra after serving as Global Chief Financial Officer of HOYA Vision Care, a $2.1 billion division of HOYA operating in more than 30 countries, where he led significant margin expansion, multiple acquisitions, and a global finance transformation across a team of more than 500. He brings nearly two decades of finance leadership in regulated medical technology and the capital-markets discipline required to support ViCentra’s next phase of growth and financing.

“Kaleido addresses a clear and growing need in diabetes care, and ViCentra has built strong commercial momentum,” commented Ian Wells, Chief Financial Officer of ViCentra. “My focus is on strengthening the financial foundation of the business to support scalable growth, disciplined capital allocation, and long-term value creation, ultimately enabling access for more people living with diabetes.”

West brings a strong combination of public-company leadership, diabetes-sector experience, and value creation in medical technology. He most recently served as President, Chief Executive Officer and Director of Nalu Medical, leading the company to its $600 million acquisition by Boston Scientific in early 2026. Previously, he served as President, Chief Executive Officer and Director of Intersect ENT, leading the company to its $1.1 billion acquisition by Medtronic in 2022. Earlier in his career, West spent 23 years at Johnson & Johnson, including leadership roles as Worldwide Vice President of Strategy and Business Development for J&J’s family of diabetes companies and Division President of LifeScan in North America and EMEA. He currently serves as an Independent Director of SI-BONE (NASDAQ: SIBN).

“ViCentra has developed a highly differentiated insulin delivery system and built strong momentum in a market I know well,” remarked Tom West, Independent Board Member at ViCentra. “The combination of a design-led system, a proven algorithm, and commercial-scale manufacturing is what it takes to build a category leader. I am glad to join the Board and help the team create lasting value for patients and shareholders as it scales in Europe and enters the United States.”

The appointments position ViCentra to accelerate adoption beyond its current base of more than 5,000 users across Germany, the Netherlands and France, expand into additional European markets, and advance preparations for U.S. market entry.

For more information, please contact:

Optimum Strategic Communications

Zoe Bolt, Katie Flint, Nellie Stephens
+44 (0) 203 882 9621
Email: [email protected]

About ViCentra
ViCentra is on a mission to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, a flexible, discreet, and beautifully crafted alternative to traditional insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry. Its investors include Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations and INKEF. More information about ViCentra can be found at www.hellokaleido.com.

About Kaleido
Kaleido is redefining the category of wearable insulin delivery as the first insulin patch pump designed with the form, function, and simplicity of a lifestyle product. Compact, featherlight, and discreet, Kaleido is designed with a focus on personal technology rather than a traditional medical device. It is made from premium materials and features customizable aluminum shells in ten color options, enabling self-expression, not just glycemic control. It offers users flexibility in how and where they wear their pump, allowing people with diabetes to manage their therapy in a way that fits seamlessly into their daily lives.

It is the smallest, lightest, most precise insulin patch pump in its class, delivering advanced, automated insulin therapy through seamless integration with Diabeloop’s clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2 and Dexcom’s G6 and G7 sensors.



Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

  • The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported
  • With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management
  • The integrated content collaboration is the first-of-its-kind between Calm and a MedTech company, built on Insulet’s global research showing the essential role emotional well-being plays in diabetes management

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech company, introducing bespoke mindfulness content, The Mind in Range Collection. The collection includes short meditations, a breathing exercise, and a new Calm Sleep Story, designed specifically for the diabetes community.

“The unmet needs and daily realities of people living with diabetes shape how we innovate and who we choose to partner with,” said Manoj Raghunandanan, Chief Growth Officer at Insulet. “Living with this condition requires constant decisions, and over time that responsibility can create real stress and anxiety. Global data suggest that nearly 80% of people living with diabetes suffer burnout from the emotional strain and demands of daily management. We hold ourselves to a clear standard: do more for people while asking less of them. Partnering with Calm recognizes the emotional dimension of diabetes and expands the support we provide beyond physical outcomes.”

Available on the Calm app and website beginning today, the collection features a suite of free-to-access mindfulness tools created for the diabetes community, which includes:

  • A Sleep Story narrated by Lila Moss, fashion model and Omnipod user living with type 1 diabetes. Lila shares a soothing narrative that helps listeners unwind and feel supported as they drift to sleep
  • A series of guided meditations to help manage stress and restore balance during moments of overwhelm
  • A breathing exercise designed to calm the mind and body, ideal for quick resets throughout the day

Global research3 from Insulet shows most people with diabetes want more holistic care—yet mental health needs remain overlooked.

  • 66% of people with diabetes and 46% of caregivers report poor‑quality sleep driven by diabetes‑related stress and anxiety
  • 62% of people with type 1 diabetes and 60% with type 2 diabetes say they want support that includes mental health and mindfulness
  • Among those using mindfulness tools, 39% report less stress and 33%less anxiety and fewer sleep problems

Studies show that mindfulness-based stress reduction can meaningfully reduce stress for people with diabetes over time. Through this partnership, Insulet and Calm aim to normalize conversations around well-being and mental health in diabetes care and make mindfulness simple and accessible.

“Mindfulness can play a powerful role in improving quality of life for people living with diabetes,” said Dr. Chris Mosunic, Calm Chief Clinical Officer. “By combining Calm’s expertise in this area with Insulet’s leadership in diabetes technology, we’re delivering tools and support that reduce cognitive burden and relieve emotional stress to improve mental wellness.”

This partnership reinforces Insulet’s position as a brand that prioritizes whole-person care and empowers healthcare professionals with credible, evidence-based resources to support their patients’ emotional well-being. The initiative will roll out globally with bespoke content available on the Calm and Calm Sleep apps and promoted across Omnipod and Calm channels throughout the year.

To learn more and explore the free guided meditations, breathing exercise, and Lila Moss’s new sleep story, visit the Omnipod × Calm page at omnipod.com/calm.

1 World Health Organization, World mental health today, 2025

2Putting wellbeing at the core of diabetes care, The Lancet Diabetes & Endocrinology, Volume 12, Issue 12, 865

3 The Global survey results are based upon the responses of 9,656 workers and workers with type 1 or type 2 diabetes across more than 10 sectors in Germany, Netherlands, Saudi Arabia, Spain, Sweden, United Kingdom, United States, Denmark, Australia, Canada, and France. Censuswide conducted an online survey on behalf of Insulet between Sept. 11 and Sept. 29, 2025. Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship of other affiliation.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

About Calm:

Calm is a leading consumer mental health company on a mission to support everyone on every step of their mental health journey. Known for its flagship consumer app—ranked #1 in its category with over 180 million downloads and availability in 10 languages across nearly 190 countries—Calm helps people sleep better, stress less, and live more mindfully through content and resources from experts and beloved celebrity voices. Building on this foundation, Calm has created a broader portfolio including evidence-based solutions like Calm Health, which is offered through employers, health plans and providers and designed to expand access to mental health and sleep support, boost benefits engagement, and drive positive health outcomes. Today, Calm supports more than 100K organizations and reaches over 39 million covered lives through Calm Health. Calm has been recognized as a TIME100 Most Influential Company and one of Fast Company’s Brands That Matter. Learn more at calm.com.

Media:

Cristal Downing

Chief Corporate Affairs Officer

[email protected]

Investor Relations:

Clare Trachtman

Vice President, Investor Relations

[email protected]

KEYWORDS: North America United States Ireland United Kingdom Europe Massachusetts

INDUSTRY KEYWORDS: Mental Health Technology Men Medical Devices Science Family Consumer Diabetes Health Health Technology Apps/Applications Research Software Teens Women Seniors Children

MEDIA:

Logo
Logo

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks

Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer’s drug candidate, PMN310, presented at AAIC 2026.

The findings, drawn from analysis of samples collected during the Company’s Phase 1a trial in healthy volunteers (NCT06105528), showed that individuals receiving PMN310 exhibited a dose-dependent reduction in detectable AβO in cerebrospinal fluid (CSF) at both three and 29 days after dosing. While healthy individuals carry lower oligomer burdens than Alzheimer’s patients, amyloid-beta oligomers are detectable in CSF even in cognitively normal adults, making this a meaningful measure of target engagement. This represents one of the first quantitative demonstrations of treatment-related oligomer reduction in humans.

“These data represent an important milestone for PMN310 and offer evidence supporting our precision medicine approach in treating Alzheimer’s disease,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “Using CSF samples from our Phase 1a study, subjects receiving PMN310 showed a clear dose-dependent reduction in oligomer particles, which, we believe, represents direct evidence that PMN310 was able to reach the brain and engage its intended target. We are grateful to our partner, attyloid, for their contribution to the assay development that made this possible, and we intend to deploy this assay in our ongoing PRECISE-AD Phase 1b trial to directly measure oligomer burden in Alzheimer’s patients before and after treatment.”

Dr. Johanne Kaplan, Chief Development Officer, ProMIS Neurosciences said, “A large body of evidence in Alzheimer’s disease research indicates that disease pathogenesis is not directly driven by plaque burden, but rather by soluble toxic amyloid-beta oligomers. Selectively targeting oligomers while avoiding plaque could have a meaningful impact on both the efficacy and safety of treatment, reducing off-target binding that limits effective dosing and potentially limiting the ARIA side effects associated with plaque-binding antibodies. We believe the data presented today provide pharmacodynamic evidence supportive of PMN310’s differentiated mechanism of action.”

Mr. Warma added, “Building on this evidence of target engagement, we look forward to sharing blinded six-month interim data from the PRECISE-AD Phase 1b trial in the coming weeks. This interim analysis will focus on blinded aggregate safety data and overall trends in selected biomarkers across study participants. Top line unblinded results are expected in early Q1 2027.” 

Key Results Presented at AAIC

Amyloid-beta oligomers in CSF were measured using surface-based fluorescence intensity distribution analysis (sFIDA) developed by attyloid GmbH, an assay which enables direct quantification of oligomer particles with unprecedented sensitivity. While the assay is currently exploratory, it provides pharmacodynamic evidence of target engagement by PMN310.

  • Oligomer reduction: Placebo-treated healthy volunteers (N=40) in the Phase 1a trial exhibited low levels of AβO in CSF.  PMN310 administration resulted in a dose-dependent reduction in detectable AβO particles in CSF.
  • Strict oligomer selectivity: PMN310 demonstrated strong binding to AβO with no interaction with monomers by surface plasmon resonance (SPR), and no detectable reactivity with plaques or vascular deposits of Aβ in AD brain tissue sections, representing the potential for a differentiated clinical profile.
  • Favorable pharmacokinetics and tolerability: PMN310 was generally well-tolerated, with CSF concentrations linearly dose-dependent, reaching 100–600 times the estimated molar concentration of AβO, and a CSF half-life of approximately 27 days.
  • Preclinical memory preservation: In a transgenic AD mouse model, PMN310 preserved memory and learning performance in the Morris Water Maze task.

AAIC Presentation details

Title: Activity and clinical progress of PMN310 designed to selectively target toxic Aβ oligomers for greater potency in Alzheimer’s disease
Date/Location: July 14, 2026, Poster presentation, AAIC Exhibit Hall, 7:30 am-4:15pm
Presenter: Dr. Johanne Kaplan, CDO, ProMIS Neurosciences



About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)

PMN310, ProMIS’ lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. This selectivity may reduce or eliminate the risk of amyloid-related imaging abnormalities (ARIA), including brain swelling (ARIA-E) and microhemorrhages (ARIA-H), which are commonly associated with plaque-binding antibodies. PMN310 was granted Fast Track Designation by the U.S. Food and Drug Administration in July 2025.

Based on encouraging results from a Phase 1a trial (NCT06105528) in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b trial to evaluate PMN310 in patients with mild cognitive impairment due to AD or mild AD. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, and 20 mg/kg) of intravenous PMN310. The study has completed enrollment of 144 participants across the three dosing cohorts who are being treated for twelve months. It is designed to provide meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s Phase 1a clinical trial, results of the use of the assay discussed in this release and intent to deploy such assay in the future, the PRECISE-AD Phase 1b clinical trial, target engagement and biomarker findings, the expected timing and nature of blinded interim and topline clinical data of PMN310, its mechanism of action and potential benefits and the Company’s development plans. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that preclinical results or early results may not be indicative of future results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K for the year ended December 31, 2025 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For further information:

Visit us at www.promisneurosciences.com

Media Contact

Maggie Whitney
LifeSci Communications
[email protected]

Investor Relations Contact

Carie Pierce
VP Investor Relations & External Affairs
[email protected]



Tower Semiconductor with METI Support Announces Strategic Capacity Expansion in Japan

Significant Multiples of Silicon Photonics and Silicon Germanium Capacity to Support Accelerating Customer Demand

MIGDAL HAEMEK, Israel, July 14, 2026 – Tower Semiconductor (NASDAQ/TASE: TSEM), a leading foundry of high-value analog semiconductor solutions, today announced a parallel dual-track strategic expansion of its 300mm Silicon Photonics (SiPho), Silicon Germanium (SiGe), and advanced packaging capabilities in Japan, with support from the Government of Japan. The expansion is designed to support the rapidly growing long-term customer demand, substantially increasing the Company’s manufacturing capacity and extending its technology leadership.

Russell Ellwanger, Tower’s CEO, stated: “We are honored and appreciative that the Government of Japan has selected Tower to lead the expansion of these strategically important technologies. Together, we are building a globally differentiated center of excellence founded on technology leadership, manufacturing excellence, and exceptional product quality.

Since becoming the majority owner of the former Panasonic Semiconductor manufacturing operations, now TPSCo, this group has established a reputation for transforming cutting-edge innovation into high-volume manufacturing excellence. For these reasons, with the support of the Government of Japan, we will create a globally differentiated, advanced R&D and manufacturing center of excellence for Silicon Photonics, Silicon Germanium, and advanced optical packaging of very significant scale.

By combining Tower’s specialized technology leadership with Japan’s unparalleled manufacturing expertise, world-class research institutions, and deeply committed workforce, we are building a strategic platform that will drive innovation, economic growth, and semiconductor leadership for decades to come.”

Track one adds significant new 300mm Silicon Photonics capacity, with full production readiness expected during the fourth quarter of 2027. It consists of repurposing the Arai facility, formerly Fab 6, for 300mm Silicon Photonics capacity and advanced packaging capabilities, maximizing the Company’s Fab 7 300mm output in Uozu. Reflecting upon the track one growth outlook, Tower is updating its business model, targeting to achieve $3.6 billion of revenue and $1.2 billion of net profit in 2028.

Track two will commence in parallel with the first track and consists of constructing an additional 300mm manufacturing facility, adjacent to Fab 7, following signing and closing of related agreements. This facility is expected to provide a multi-fold increase in Silicon Photonics and Silicon Germanium capacity, positioning Tower to support continued accelerating customer demand for emerging AI and data center applications, driving next-generation optical connectivity requirements.

As a result of expanded customer engagements, and significant technical milestones achieved through multi-generation strategic partnerships, the new facility is expected to be highly accretive beginning in 2029, demonstrating strong leadership in the optical space, promoting long-term employee pride and strong customer satisfaction, with a business model ensuring long-term viability.

The scope of the dual-track expansion is forecasted to be an approximate $3 billion Tower’s investment, net of grants of $1 billion, to be provided by the Government of Japan. This investment creates long-term value for both Tower and Japan by establishing advanced domestic manufacturing capabilities in Silicon Photonics and Silicon Germanium, strengthening Japan’s semiconductor ecosystem and supply chain resilience.

Ellwanger further added: “Building on our long-standing relationships with Toyama and Niigata Prefectures and supported by our significant investments in the Uozu and Arai facilities, we look forward to deepening our collaboration to strengthen regional semiconductor infrastructure, expand local supply-chain capabilities, accelerate innovation, developing the next generation of highly skilled engineering and manufacturing talent, a workforce renowned for its commitment, individual ownership, dedication and loyalty.

Tower is dedicated to sustaining and creating high-quality employment, recruiting, developing, and retaining world-class engineering and manufacturing talent, expanding collaboration with local suppliers and businesses, and deepening partnerships with Japanese universities and research institutions. By strengthening these industrial and academic ecosystems, Tower seeks to drive innovation, enhance regional competitiveness, and contribute to the sustainable growth and long-term economic development of both prefectures.”

Ellwanger concluded: “The first track results in substantial increases in our updated 2028 business model. By quickly and efficiently adding capacity to an existing profitable operation, track two eliminates the timing concerns and impacts of multi cycles of learning for a greenfield qualification or a fab-to-fab product transfer, ensuring on schedule customer ramps and cash flow. We anticipate track two to provide the path for continued growth far beyond 2028.”

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, provides technology, development, and process platforms for its customers in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor focuses on creating a positive and sustainable impact on the world through long-term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiPho, SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, displays, integrated power management (BCD and 700V), and MEMS. Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor currently owns one operating facility in Israel (200mm), two in the U.S. (200mm), and two in Japan (200mm and 300mm) which it owns through its 51% holdings in TPSCo and shares a 300mm facility in Agrate, Italy with STMicroelectronics. For more information, please visit: www.towersemi.com.

Forward-Looking Statements

This release, as well as other statements and reports filed, stated and published, include certain “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, projections and statements with respect to our future business, financial performance and activities. The use of words such as “projects”, “expects”, “may”, “targets”, “plans”, “forecast”, “intends”, “committed to”, “tracking”, or variations or words of similar import, may identify a statement as “forward-looking.” However, the absence of these words does not mean that a statement is not forward-looking. Actual results may vary from those projected or implied by such forward-looking statements and you should not unduly rely on such forward-looking statements, which speak only as of the date of this release. Factors that could cause actual results to differ materially from those projected or implied by such forward-looking statements include, without limitation, risks and uncertainties associated with: (i) fluctuating demand in our customers’ end markets and/or SiPho, SiGe and other customer demand may not increase to the levels currently forecasted by the Company, (ii) reliance on acquisitions, establishing new fabs and/or gaining additional capacity for growth, (iii) difficulties in achieving acceptable operational metrics and indices as a result of operational, technological or process-related problems, (iv) identifying and negotiating with third-party buyers for the sale of any excess and/or unused equipment, inventory and/or other assets, (v) maintaining current key customers and attracting new key customers, (vi) over demand for our foundry services and/ or products that may result in operational bottlenecks, extend cycle times, reduce yield, delay delivery schedules, that may result in compensation, penalties and/ or prepayment repayments, loss of customers, revenues, profits and/ or reputation, including with respect to SiPho customer prepayments received for certain minimum capacity commitments, due to inability to fulfill, in whole or in part, all such demand and commitments in a timely manner or at all, (vii) fluctuation of our financial results from quarter to quarter, (viii) the additional 300mm manufacturing facility the Company plans to establish adjacent to Fab 7 and maximization of the Company’s Fab 7 300mm output (including risks associated with the repurposing of the Arai facility), including risks associated with delays in construction period and cost, obtaining necessary equipment and/ or obtaining necessary permits, Government of Japan and/or METI grants terms and covenants thereto (which may result in loss of a portion or all of the grant funds), and/ or other consents required, and the negotiation of definitive agreements with vendors and others, that may result in lower profitability than currently expected and/ or added costs and losses, longer return on investment period, including risks associated with the ability to obtain any financing required to fund the establishment, facilities and machinery cost net investments on favorable terms, or at all, (ix) our debt and other liabilities may impact our financial position and operations, (x) our ability to successfully execute acquisitions, integrate them into our business, utilize our expanded capacity and find new business, (xi) fluctuations in cash flow, (xii) our ability to satisfy the covenants stipulated in our agreements with our debt holders and/ or possible incurrence of additional indebtedness, (xiii) pending litigation, (xiv) meeting the conditions set in approval certificates and other regulations under which we received grants and/or royalties and/or any type of funding from the Israeli, US and/or Japan governmental agencies, (xv) receipt of orders that are lower than the customer purchase commitments or forecast and/or failure to receive customer orders currently expected, (xvi) the effects of global recession, credit crisis and/or unfavorable macro-economic conditions, such as the imposition of regulatory requirements, tariffs, import and export restrictions and other trade barriers and restrictions, including the timing and availability of export licenses and permits, (xvii) our ability to accurately forecast financial performance, which is affected by limited order backlog and lengthy sales cycles which may cause financial results to fluctuate from quarter to quarter, (xviii) possible situations of obsolete inventory or overcapacity if forecasted demand exceeds actual demand when we create inventory before receipt of customer orders, (xix) the cyclical nature of the semiconductor industry and the resulting periodic overcapacity, fluctuations in operating results and future average selling price erosion, (xx) capacity and capability expansion and acquisition related transactions in our existing fabrications, strategic and/or other in-organic capacity and/ or capability growth and/ or M&A transactions and opportunities, and/ or the acquisition of and/ or the establishment of a new factory or factories, including the additional 300mm manufacturing facility the Company plans to establish adjacent to Fab 7 and maximization of the Company’s Fab 7 300mm output (including risks associated with the repurposing of the Arai facility), which could require funding needs beyond our existing cash, the availability of which cannot be assured on favorable terms, if at all, and which may have adverse impact on the market value of the Company and the price of the Company’s ordinary shares, (xxi) operating our facilities at sufficient utilization rates necessary to generate and maintain positive and sustainable gross, operating and net profit, (xxii) the purchase of equipment and/or raw material (including purchases under committed contracts), the timely completion of the equipment installation, technology transfer and raising the funds therefor, (xxiii) product returns and defective products, (xxiv) our ability to maintain and develop our technology processes and services to keep pace with new technology, including artificial intelligence, evolving standards, changing customer and end-user requirements, new product introductions and short product life cycles, (xxv) competing effectively, (xxvi) our dependence on increased use of outsourced foundry services for specialty process technologies, (xxvii) our dependence on intellectual property rights of others, our ability to operate our business without infringing others’ intellectual property rights and our ability to enforce our intellectual property against infringement, including risks and uncertainties associated with the three infringement claims that the Company is currently party to, brought by GlobalFoundries alleging infringement of certain of its patents, (xxviii) Fab 3 landlord’s alleged claims regarding noise abatement and request for judicial declaration of material non-curable breach of the Fab3 lease, and in addition, claims by a third-party with whom the landlord is engaged pertaining to the Fab3 site, where such third party believes he has certain rights with respect to the lease extension, (xxix) retention of key employees and recruitment and retention of skilled qualified personnel, (xxx) exposure to inflation, currency rates (mainly the Israeli Shekel and the Japanese Yen) and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the market price of our traded securities, (xxxi) meeting regulatory requirements worldwide, including export, environmental and governmental regulations, as well as risks related to international operations, (xxxii) engagements for fab establishment, joint venture and/or capital lease transactions for capacity enhancement in advanced technologies, including risks and uncertainties associated with the Agrate fab, such as its qualification schedule, technology, equipment and process qualification, facility operational ramp-up, customer engagements, cost structure, required investments and other terms, which may require additional funding to cover significant capacity investment needs and other payments, (xxxiii) potential liabilities, cost and other impact due to reorganization and consolidation of fabrication facilities, or cessation of operations, (xxxiv) potential security, cyber and privacy breaches, (xxxv) workforce that is not unionized which may become unionized, and/or workforce that is unionized and may take action such as strikes that may create increased cost and operational risks, (xxxvi) the issuance of ordinary shares as a result of exercise and/or vesting of any of our employee equity, as well as any sale of shares by any of our shareholders, or any market expectation thereof, as well as the issuance of additional employees’ restricted stock units, or any market expectation thereof, which may depress the market value of the Company and the price of the Company’s ordinary shares, and in addition may impair our ability to raise future capital, (xxxvii) the dispute resolution process with involving Intel’s determination not to perform its agreement to build a capacity corridor to enable Intel to manufacture wafers for Tower’s customers, which process may be costly and/ or may result in losses and/or other adverse impact, (xxxviii) Pillar Two tax rules and regulations previously released by the OECD, which require a minimum effective corporate income tax rate of 15% applicable in every jurisdiction in which the company operates, which will result in additional income tax expenses for the years 2026 and beyond, mainly with respect to the Company’s Israeli operations in which the Company was subject to 7.5% preferred tax rate until 2025 under Israeli laws, and (xxxix) climate change, business interruptions due to floods, fires, pandemics, earthquakes and other natural disasters, the security situation in Israel and global trade “war”, including the potential inability to continue uninterrupted operations of the Israeli fab, impact on global supply chain to and from the Israeli fab, delays in the delivery, installation and qualification of equipment, power interruptions, chemicals or other leaks or damages as a result therefrom, absence of workforce due to military service as well as risk that certain countries will restrict doing business with Israeli companies, including imposing restrictions due to hostilities in Israel or political instability in the region that may continue or exacerbate, and other events beyond our control. Due to hostilities and instability in neighboring states, Israel could be subject to additional political, economic, and military confines, and our Israeli facility’s operations could be materially adversely affected. Any current or future hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic or financial condition of Israel, could have a material adverse effect on our business, financial condition and results of operations.

A more complete discussion of risks and uncertainties that may affect the forward-looking statements included in this release or which may otherwise affect our business is included under the heading “Risk Factors” in the Company’s most recent filings on Forms 20-F and 6-K, as were filed with the SEC and the Israel Securities Authority. Future results may differ materially from those previously reported. The Company does not intend to update and expressly disclaims any obligation to update
or revise any forward-looking information contained in this release
to reflect any changes in expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement is based.

                                                ###
Tower Semiconductor Company Contact: Orit Shahar | +972-74-7377440 | [email protected]
Tower Semiconductor Investor Relations Contact: Liat Avraham | +972-4-6506154 | [email protected]

Attachment